FDA/CDC Approve Pfizer Booster for 16- and 17-Year Olds

12/9/21 — The FDA amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine, authorizing the use of a single booster dose for administration to individuals 16 and 17 years of age at least six months after completion of primary vaccination with the Pfizer-BioNTech COVID-19 Vaccine. The CDC followed up on FDA’s action by likewise expanding its COVID-19 booster recommendations. Read the FDA statement. Read the CDC statement.